ProCE Banner Activity

Experts Answer Key Questions on Novel Therapies for Hemophilia Prophylaxis

Clinical Thought

What questions do you have on hemophilia prophylaxis? Read expert responses to questions from a live event at the Thrombosis & Hemostasis Summit of North America on new therapies for hemophilia prophylaxis.

Released: June 05, 2024

Expiration: June 04, 2025

Share

Faculty

Mark T. Reding

Mark T. Reding, MD

Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
Minneapolis, Minnesota

Guy Young

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Sanofi.

Sanofi

Disclosure

Primary Author

Mark T. Reding, MD

Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota Medical Center
Minneapolis, Minnesota

Mark T. Reding, MD: researcher (paid to institution): Bayer, Biomarin; consultant/advisor/speaker: Bayer, Biomarin, CSL Behring, Genentech, Hema Biologics, Novo Nordisk, Sanofi, Spark, Takeda.

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Guy Young, MD: consultant/advisor/speaker: BioMarin, Centessa, CSL Behring, Genentech/Roche, Hema Biologics, Novo Nordisk, Octapharma, Pfizer, Sanofi, Spark, Takeda.